DEFINITIVE CONTRACT
Active75N93026C00010
Department of Health and Human Services › National Institutes of Health › NATIONAL INSTITUTES OF HEALTH NIAID
$1.9M
obligated · signed 3 months ago
TO DEVELOP AND CLINICALLY VALIDATE AN INNOVATIVE CELL-FREE DEOXYRIBONUCLEIC ACID (CFDNA) BASED PANEL FOR DETECTING DISEASE-CAUSING FUNGI DIRECTLY FROM PLASMA.
Performance timeline
Start
Aug 3, 2026
End
Apr 30, 2027
with all options
Loading status
This contract is likely in the recompete window
Ends with all options: Apr 30, 2027
ZEPTO LIFE TECHNOLOGY, INC.
Contract 75N93026C00010
UEI
ELTELWNJZJ73
Parent Company
ZEPTO LIFE TECHNOLOGY, INC.
Capabilities & Certifications
Headquarters Location
Congressional District: 04
Current Obligation
$1,878,981
Base + Exercised Options
$1,878,981
Total Ceiling Value
$8,946,929
Contract Type
COST NO FEE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Place of Performance
Congressional District: 04
Awarding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH NIAID
Office
Funding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH NIAID
Office
Solicitation procedures, competition exceptions, labor standards and account totals.